Clik here to view.
InnoCare Presents Latest Clinical Data of Orelabrutinib at the 62nd Annual...
BEIJING InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today three presentations of the most recent clinical data with orelabrutinib, its BTK inhibitor, at the 62nd...
View ArticleClik here to view.
TAE Life Sciences and Neuboron Medtech Announce Joint Venture Aimed at...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS) today announces a new joint venture (JV) agreement with Neuboron Medtech (Neuboron) for the widespread adoption of Accelerator-based Boron Neutron...
View ArticleClik here to view.
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth...
OSAKA, Japan As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the...
View ArticleClik here to view.
Mojo Vision and Menicon Announce Joint Development Agreement on Smart Contact...
SARATOGA, Calif. Mojo Vision, the Invisible Computing company, and Menicon, Japan’s first and largest contact lens manufacturer, today announced that both companies have entered into a joint...
View ArticleClik here to view.
Rhizen...
スイス・ラショードフォン （ビジネスワイヤ） — オンコロジー分野に傾注する臨床段階のバイオ製薬企業であるRhizen Pharmaceuticalsは本日、来る2020年12月5～8日にバーチャル開催される第62回米国血液学会（ASH）年次大会・展示会で、再発性／難治性T細胞リンパ腫患者でテナリシブとロミデプシンの併用療法を検討する第1／2相試験の中間結果を報告すると発表しました。...
View ArticleClik here to view.
Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug...
View ArticleClik here to view.
Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a global company...
View ArticleClik here to view.
D. One Vision Management Leads $16 Million Series A Investment In PrinterPrezz
NEW YORK D. One Vision Management with its DOV Singularity Fund, an alternative investment vehicle for investors seeking growth and diversification in tech-empowered future, today announced the...
View ArticleClik here to view.
Results from First Combination Trial of ENHERTU® and Immune Checkpoint...
TOKYO & BASKING RIDGE, N.J. & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today presented the first immunotherapy combination study results for ENHERTU®...
View ArticleClik here to view.
ENHERTU® Continues to Demonstrate Durable Responses with New Data from...
TOKYO, MUNICH & BASKING RIDGE, N.J. Updated results from the positive phase 2 DESTINY-Breast01 trial show Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU®...
View ArticleClik here to view.
Clik here to view.
武田在ASH 2020上呈报真实世界证据，展现其对罕见出血性障碍个体化治疗的长期承诺
马萨诸塞州剑桥和日本大阪 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE:TAK)（“武田”）今天在美国血液学会(ASH)第62届年会暨展会上呈报5篇血液学壁报和4篇摘要，强调了其促进罕见出血性障碍治疗的承诺。武田还将在会上呈报其更强大的肿瘤产品阵容和产品管线。在这里阅读更多内容，请点击此处。...
View ArticleClik here to view.
Clik here to view.
Complimentary Ticket to Join YAFO ACCESS CHINA Forum 2021
SHANGHAI YAFO Life Science and BioToChina.org announced the schedule for ACCESS CHINA Forum 2021 (January 4th - 22nd). As the largest China corporate access event during the JPM Conference weeks,...
View ArticleClik here to view.
D. One Vision Management领投PrinterPrezz 1600万美元A轮融资
纽约 D. One Vision Management及其旗下另类投资基金DOV Singularity Fund今天宣布已将全球首家医疗制造（MedifacturingTM）公司PrinterPrezz纳入其投资组合。该基金面向希望在科技赋能的未来实现财富增长和多元化的投资者。通过DOV Singularity Fund，D. One Vision...
View ArticleClik here to view.
新研究提示，Masimo SpHb®无创连续血红蛋白监测作为患儿血液管理的一部分，可减少ICU留住时间和术后输血
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天发布Euroanaesthesia 2020上最新呈报的一篇摘要的结果，该研究中，土耳其伊斯坦布尔马尔马拉大学的Saraçoğlu博士及其同事调查Masimo无创连续血红蛋白监测SpHb®作为接受大手术的患儿输血管理组成部分的有效性1。研究人员发现，使用SpHb可降低术后输血率、缩短ICU留住时间、改善其他转归。...
View ArticleClik here to view.
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of TROPION-Lung05, a global phase 2 trial of...
View ArticleClik here to view.
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of TROPION-Lung01, a global pivotal phase 3...
View ArticleClik here to view.
Propanc Biopharma Provides Shareholder Update
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
研究人员采用Masimo ORi™（氧储备指数）帮助抑制乳房手术患者的术后高氧
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天发布Euroanaesthesia 2020上最新呈报的一篇摘要的发现，该研究中，日本矢巾町岩手医科大学医院Kumagai博士及其同事调查Masimo ORi™（氧储备指数）能否用于限制术后高氧的程度1。研究人员的结论是，ORi可帮助“抑制高氧、预防缺氧”。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View Article